Keros Therapeutics (KROS) Announces Review of Strategic Alternatives
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Keros Therapeutics Announces Review of Strategic Alternatives
April 10, 2025 6:00 AM EDTAdopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros or the Company) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins, today announced that its Board of Directors (the Board) has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In... More
